Since the first robot-assisted surgery was performed, over 40 years ago, major advances in robotics, computer vision and artificial intelligence have fundamentally changed medicine and healthcare. Innovative new technologies are already aiding skilled medical professionals in diagnosis, surgery, rehabilitation and beyond. But many questions remain: What ethical issues arise as medical tools become increasingly autonomous? How do we regulate technologies that can learn and change over time? And how can we ensure that cutting-edge medical devices are accessible to all?
In this special live recording at the Great Exhibition Road Festival in London, Claire chatted to George Mylonas (Imperial College London), Antonia Tzemanaki (University of Bristol) and Tom Vercauteren (King’s College London) about robotics and AI in medicine and healthcare.
George Mylonas is an Associate Professor in Robotics and Technology in Cancer at Imperial College London, and the director of the Human-centred Automation, Robotics and Monitoring in Surgery lab at The Hamlyn Centre, Institute of Global Health Innovation and the Department of Surgery & Cancer, Faculty of Medicine. He is leading research in the areas of surgical robotics, soft robotics, minimal access surgical technology, perceptual human-robot and human-computer interfaces, and smart data-driven operating theatres. He is a member of the European Association of Endoscopic Surgery Technology Committee.
Antonia Tzemanaki is a Senior Lecturer in Robotics at the University of Bristol and a core member of the Bristol Robotics Laboratory. She leads the Dexterous Manipulation and Wearable Robotics group which develops robotic simulators and interventions, including robotic needle steering, abdominal, urology, skull and hand models, for surgical and physical therapy treatments of disease including cancers, neurological, prostate and urinary disorders. The group provides wide expertise in precision manipulation, robot hands, hand exoskeletons, kinematics, haptics and wearable robotics, especially with applications in surgery, preventative medicine, rehabilitation, physiotherapy and dexterous tele-operation.
Tom Vercauteren is a Professor of Interventional Image Computing at King’s College London, where he leads the Contextual Artificial Intelligence for Computer Assisted Interventions research group. His research focuses on medical image computing, machine learning and imaging for surgery and interventional sciences. He is also co-founder and Chief Scientific Officer of Hypervision Surgical, a spin-out company developing safe, non-invasive optical imaging for use during surgery. His work is now used in hundreds of hospitals worldwide. Tom is also a supporter of open-source software and patient involvement.
Drug discovery has always been a high-stakes function in pharma, but the pressure on R&D teams has grown significantly. Rising development costs, tighter patent windows, and increasing competition are forcing pharmaceutical leaders to rethink how innovation is delivered.
Improving pipeline productivity is no longer only about scientific progress. It is directly tied to business growth, speed to market, and long-term competitiveness. For many pharmaceutical organizations, the bigger challenge is not failed drugs but the cost of making the wrong decisions too late in the pipeline.
This is where Artificial Intelligence (AI) is creating real momentum. By improving how research teams analyze data, identify targets, evaluate molecules, and manage risk, AI is helping pharmaceutical organizations make faster and better decisions across the drug discovery lifecycle.
McKinsey estimates that generative AI could contribute between $60 billion and $110 billion annually across pharma and medical products, with drug discovery representing one of the highest-value areas. For pharma leaders, the opportunity is becoming increasingly clear: better decisions earlier in the process can significantly improve outcomes across the entire pipeline.
AI is changing the way pharmaceutical organizations approach discovery by improving how data is analyzed, decisions are made, and risks are identified earlier in the pipeline. From target identification to clinical readiness, its role is expanding across every critical stage of drug development.
Every stage of pharmaceutical research starts with data. Genomics, biomarkers, molecular libraries, proteomics, and patient records have expanded the amount of information available to R&D teams at an unprecedented scale.
But data volume alone does not improve decision-making.
One of the biggest bottlenecks in modern drug discovery is identifying which data points deserve action. Delays at this stage often affect everything that follows, from target validation to candidate progression.
AI is helping solve this by improving how complex datasets are processed and interpreted. Machine learning models can identify biological patterns, protein interactions, and disease relationships faster than traditional analysis methods.
In practical use cases, this supports faster biomarker discovery, disease pathway mapping, and stronger hypothesis generation.
Recommended To read: How Generative AI Speeds Up Drug Discovery and Development?
Once data is structured and understood, the next critical decision is target selection.
Target identification determines where scientific effort, budgets, and resources will be invested. Weak target selection often creates years of downstream inefficiency and unnecessary spend.
AI is helping improve this process by analyzing biological and historical datasets to identify high-potential targets faster.
Common applications include identifying novel oncology targets, prioritizing rare disease gene mutations, and mapping inflammatory pathway markers for therapeutic development.
For pharmaceutical leaders, stronger target confidence improves portfolio discipline and reduces investment in lower-probability programs.
In many pharma delivery engagements, stronger target quality early has consistently increased the efficiency of the broader pipeline.
After a target is selected, the next challenge is identifying molecules that can interact effectively with it. This phase has traditionally depended on repeated screening and refinement cycles, making it one of the most time-intensive and expensive parts of R&D.
AI is helping make this process more predictive, especially in therapeutic areas where molecular complexity makes traditional screening slower, more expensive, and harder to scale.
Generative models can evaluate thousands of molecular structures based on efficacy, stability, and binding affinity before physical testing begins.
This supports several important use cases:
Deloitte has highlighted how AI is improving efficiency in discovery environments where repeated experimentation has historically slowed progress.
For leadership teams, this translates into faster candidate progression and more focused R&D investment.
As candidates move deeper into development, the cost of failure increases significantly. Late-stage toxicity remains one of the most expensive risks in pharma. A candidate can progress for years before safety concerns emerge, affecting both budgets and pipeline strategy.
Predictive AI models are helping reduce this risk earlier. By analyzing historical toxicity datasets, AI can identify potential hepatotoxicity, cardiotoxicity, and broader compound safety concerns before preclinical testing begins. This gives pharmaceutical teams earlier visibility into candidate quality.
For business leaders, earlier risk detection improves capital efficiency and strengthens decision-making across active portfolios.
Clinical trials remain one of the longest and most operationally complex stages in pharmaceutical development. Delays in patient recruitment, poor cohort alignment, and protocol inefficiencies can significantly extend development timelines.
AI is helping improve trial readiness by supporting more data-driven planning. By analyzing patient records, historical trial performance, and disease progression patterns, AI can improve cohort matching, predict enrollment bottlenecks, and optimize site selection.
These use cases improve trial preparation and reduce avoidable delays. For pharmaceutical leaders, stronger trial readiness directly affects time-to-market and the ability to maximize commercial opportunities.
As candidates move closer to commercialization, the focus begins to shift from scientific validation to regulatory readiness, where operational efficiency becomes equally important.
AI’s role in pharma is expanding beyond discovery and trials. Regulatory workflows involve significant effort across documentation review, compliance checks, and submission preparation. These tasks often create operational slowdowns close to market entry.
AI is helping improve this through intelligent document processing. Key applications include:
For pharmaceutical organizations, this reduces administrative burden and improves operational efficiency during critical submission stages.
The conversation around AI in pharma has shifted significantly in recent years. What started as isolated innovation projects is now becoming part of broader R&D strategy. Pharmaceutical companies are increasing AI investments because the business value is becoming clearer, from faster research cycles to stronger candidate quality and better risk visibility.
One of the biggest reasons AI initiatives stall in pharma is not model capability. It is fragmented research data and poor integration into scientist workflows.
This is where execution becomes critical.
In many AI-led pharma engagements supported by USM Business Systems, the focus has been on turning AI into practical solutions across drug discovery, from biomedical data intelligence to predictive modeling and workflow automation.
For pharma leaders, that shift from experimentation to execution is where long-term value starts to take shape.
The next phase of AI adoption in pharma will be shaped by practical execution. For some organizations, the priority may be improving data intelligence. For others, it may begin with target selection, toxicity prediction, or clinical trial optimization.
What matters most is identifying where inefficiencies exist today and understanding how AI can improve decision quality in those specific areas.
In pharma, speed matters. But better decisions matter more. The organizations combining scientific expertise with AI-driven decision intelligence will be the ones building stronger pipelines, reducing avoidable risk, and bringing therapies to market with greater confidence.
Where can AI create the biggest impact across your drug discovery pipeline today?
Connect with USM Business Systems to explore practical AI strategies aligned to your R&D goals.